Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hepatitis A Preventive Vaccines market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Hepatitis A Preventive Vaccines market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hepatitis A Preventive Vaccines market.
- Analysis of key recent licensing and partnership agreements in Hepatitis A Preventive Vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis A Preventive Vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hepatitis A Preventive Vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis A Preventive Vaccines market landscape? – Identify, understand and capitalize. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Hepatitis A Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Historical Vaccination Coverage (2006-2011)
2.2.2 Forecast Vaccination Coverage (2011-2019)
2.3 Prognosis
2.4 Etiology
2.5 Pathophysiology
2.6 Signs and Symptoms
2.7 Diagnosis
2.8 Treatment and Management Options
2.9 Referral Pathway
2.10 GlobalData Pipeline Report Guidance
3 Hepatitis A Preventive Vaccines - Market Characterization
3.1 Global Hepatitis A Preventive Vaccines Market Size (2006-2011)
3.2 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Global
3.3 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The US
3.4 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The US
3.5 Hepatitis A Preventive Vaccines Market Size (2006-2011) - France
3.6 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - France
3.7 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Germany
3.8 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Germany
3.9 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Italy
3.10 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Italy
3.11 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Spain
3.12 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Spain
3.13 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The UK
3.14 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The UK
3.15 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Japan
3.16 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Hepatitis A Preventive Vaccines Market
3.17.1 Drivers for the Hepatitis A Preventive Vaccines Market
3.17.2 Barriers for the Hepatitis A Preventive Vaccines Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Hepatitis A Preventive Vaccines - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed class of Products in the Hepatitis A Market
4.3.1 Havrix
4.3.2 Vaqta
4.3.3 Twinrix
4.3.4 Ambirix
4.3.5 Avaxim
4.3.6 Epaxal
4.4 Key Takeaway
5 Hepatitis A Preventive Vaccines - Clinical Trials Mapping
5.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
5.2 Clinical Trials by Phase
5.3 Clinical Trials by Trial Status
5.4 Prominent Sponsors
5.5 Clinical Trials by Overall Sponsors
5.6 Top Companies Participating in Hepatitis A Preventive Vaccines Clinical Trials
6 Hepatitis A Preventive Vaccines - Strategic Assessment
6.1 Key Events Impacting the Future Market
6.2 Hepatitis A Preventive Vaccines: Implications for Future Market Competition
7 Hepatitis A Preventive Vaccines - Future Players
7.1 Introduction
7.2 Company Profiles
7.2.1 GlaxoSmithKline
7.2.2 Merck & Co
7.2.3 Crucell
8 KOL Insights
9 Hepatitis A Preventive Vaccines - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Forecasting
9.4.4 Primary Research
9.4.5 Expert Panel Validation
9.5 Contact Us
9.6 Disclaimer

1.1 List of Tables
Table 1: Comparison between Hepatitis A, B and C
Table 2: HAV Endemicity by Region
Table 3: Vaccination Coverage (In Percentage)
Table 4: Vaccination Coverage (In Percentage)
Table 5: History and Physical Examination
Table 6: Laboratory and Other Studies for Hepatitis A
Table 7: Differential Diagnosis of hepatitis A
Table 8: Havrix Dosage and Schedule for Vaccination
Table 9: Vaqta Dosage and Schedule for Vaccination
Table 10: Twinrix Dosage and Schedule for Vaccination
Table 11: UK Guidelines For Hepatitis A Vaccination
Table 12: Japanese Hepatitis A Vaccine, Dosage and Schedule
Table 13: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011
Table 14: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019
Table 15 Hepatitis A Preventive Vaccines Market, The US, Revenue ($m), 2006-2011
Table 16: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019
Table 17: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011
Table 18: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019
Table 19: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011
Table 20: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019
Table 21: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011
Table 22: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019
Table 23: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011
Table 24: Hepatitis A Preventive Vaccines, Spain, Forecast ($m), 2011-2019
Table 25: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011
Table 26: Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019
Table 27: Hepatitis A Market, Japan, Revenue ($m), 2006-2011
Table 28: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019
Table 29: Hepatitis A Preventive Vaccines - Clinical Trials by Region/ Country, 2012
Table 30: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012
Table 31: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012
Table 32: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012
Table 33: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012
Table 34: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012

1.2 List of Figures
Figure 1: Prevalence of Hepatitis A Virus by Region
Figure 2: Incidence of Hepatitis A, 1980-2009
Figure 3: Pathophysiology of Hepatitis A
Figure 4 : Symptoms of Hepatitis A infection
Figure 5: Referral Pathway for HAV Vaccination
Figure 6: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan
Figure 7: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011
Figure 8: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019
Figure 9 Hepatitis A Preventive Vaccines, The US, Revenue ($m), 2006-2011
Figure 10: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019
Figure 11: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011
Figure 12: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019
Figure 13: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011
Figure 14: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019
Figure 15: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011
Figure 16: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019
Figure 17: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011
Figure 18: Hepatitis A Preventive Vaccines Market, Spain, Forecast ($m), 2011-2019
Figure 19: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011
Figure 20 : Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019
Figure 21 : Hepatitis A Preventive Vaccines Market, Japan, Revenue ($m), 2006-2011
Figure 22: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019
Figure 23: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines Market, 2012
Figure 24: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan
Figure 25: Hepatitis A Preventive Vaccines - Strategic Competitor Assessment, 2012
Figure 26: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan
Figure 27: Hepatitis A Preventive Vaccines - Clinical Trials by Country, 2012
Figure 28: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012
Figure 29: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012
Figure 30: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012
Figure 31: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012
Figure 32: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012
Figure 33: Hepatitis A Preventive Vaccines Market - Drivers and Restraints 2012
Figure 34: Implications for Future Market Competition in Hepatitis A Preventive Vaccines Market, 2012
Figure 35: Hepatitis A Preventive Vaccines - Marketed Products by Company, 2012
Figure 36: KOL Insights, Hepatitis A Preventive Vaccines, Major Market
Figure 37: GlobalData Market Size Estimation
Figure 38 : GlobalData Market Forecasting Model

Holidayers Revive Hepatitis A Vaccine Market.

Tourists represent the biggest at-risk group for contracting hepatitis A, according to new findings released by pharmaceuticals intelligence provider GlobalData.

The new report* indicates that, to combat this, vaccinations are expected to become more common in correlation with an increase in global travel, which is introducing individuals to geographic areas with a higher risk of HAV infection.

Market growth for HAV vaccines has been only moderate in recent years due to a lack of awareness or symptoms, and the fact that vaccination is not mandatory in most countries. However, following cases such as the epidemic of HAV in Puglia, southern Italy, in 1998, the use of hepatitis A preventive vaccines rose dramatically among adolescents and toddlers.

Future increases in vaccination coverage for hepatitis A will rely on awareness programs about viral hepatitis by bodies such as Sistema Epidemiologico Integrato dell'Epatite Virale Acuta (SEIEVA) in Europe, and the Centers for Disease Control and Prevention (CDC) in the US.

The available vaccines for HAV are already very successful, boasting a high efficacy of almost 90% and displaying a high safety profile, with less than 1% of patients suffering serious adverse events. As a result, little scope is left to tempt new drug entrants in the near future and no novel vaccines are expected to emerge in the near future. However, opportunity lies in the development of an oral hepatitis A vaccine which could be available in single doses, as currently many people fail to take their additional second “booster” vaccine.

HAV is an acute infectious disease of the liver, transmitted person-to-person by the ingestion of contaminated food or water, or through direct contact with an infectious person. Hepatitus is often asymptomatic in young children, but adults often suffer symptoms including fatigue, fever, nauseau, and abdominal pain. Exposure to HAV does not cause chronic infection or liver disease, but very rare cases of acute liver failure have resulted from HAV infections.

GlobalData’s analysis shows that the global hepatitis A preventive vaccines market stood at $874.8m in 2006 and grew at a compound annual growth rate (CAGR) of 7.3% to reach $1,245.4m in 2011. GlobalData forecasts that the global hepatitis A preventive vaccines market will grow at a CAGR of 4.8% over the next eight years to reach $1,805.8m by 2019, helped along by awareness campaigns boosting the vaccine market in developed economies.

* Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

This report is an essential source of information and analysis on the global hepatitis A preventive vaccines market. It identifies the key trends shaping and driving the global hepatitis A preventive vaccines market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis A preventive vaccines market sector.

GlaxoSmithKline
Merck & Co
Crucell